ecancermedicalscience

Special Issue

Close cooperation with Health Technology Assessment expertise is crucial for implementation and ultimately reimbursement of innovations in oncology

28 Oct 2016
WH van Harten, VP Retèl

The Organisation of European Cancer Institutes OECI working group on Health Economics and Cost Benefit in Oncology suggests four actions that are needed to improve alignment and integration between clinicians, researchers, and Health Technology Assessment (HTA) experts and agencies: 1) HTA expertise is necessary close to or within the comprehensive cancer centres (CCC); 2) HTA expertise should be physically present throughout the translational research process; 3) Appropriate knowledge is necessary within the research staff; 4) Close cooperation between translational researchers, clinicians, and health economists guarantees clinical ownership.

Fulfilling these conditions may help the translational research field in oncology to interact with agencies and efficiently move innovative technologies through the translational research stages into that of implementation and diffusion. This brings innovative treatments faster to the patient with a greater chance of reimbursement.

Article metrics: 603 views
275
328

Related Articles

Lekha Madhavan Nair, KM Jagathnath Krishna, Aswin Kumar, Susan Mathews, John Joseph, Francis Vadakkumparambil James
Hugo Tanaka, Deise Uema, Juliana FM Rego, Rui F Weschenfelder, Nathalia D’Agustini, Duilio R Rocha Filho, Juan M O'Connor, Romina Luca, Jose Eduardo R Nuñez, Milton José de Barros e Silva, Rachel P Riechelmann
Ana Karla Uribe Rivera, Andres Guevara Jabiles, Ivan Chavez Passiuri, Elica Garcia Leon, Melvy Guerrero Quiroga, Renier Cruz Baca, Jossue Espinoza Figueroa, Nelson Purizaca Rosillo, Eduardo Payet Meza
Yek-Ching Kong, Veni-Venusha Sakti, Richard Sullivan, Nirmala Bhoo-Pathy
Rima A Abdul-Khalek, Ghassan Abu-Sitta, Nassim El Achi, Walaa Kayyal, Ahmad Elamine, Aba Noubani, Marilyne Menassa, Fahad Ahmed, Richard Sullivan, Deborah Mukherji